Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the transcript. The company remains a net debt free company as of March 31, 2024. There is mention of increased growth capital available with the new promoter Nirma Limited, but this refers to internal capital allocation rather than external fundraising. Capex plans are underway, with INR129 crores spent in FY '24 and new capacities starting operations in FY '25. Management focuses on calibrated capacity expansion based on business visibility, using existing resources. No indications or plans disclosed for raising funds throu

Any current/future capex/capital investment/strategic investment?

FY '25 Capex: Around INR340 crores planned. Major part (~INR140 crores) allocated for greenfield site development at Sholapur. Remaining capex to complete brownfield projects at Ankleshwar and Dahej. Regular maintenance, R&D, and quality-related capex also included. Capacity additions planned: ~208 KL at Ankleshwar (Plant 18), ~35 KL in pharma area 4 at Dahej. Sholapur capacity (approx. 500 KL) expected by late FY '26, with phased commissioning. Potential additional 120 KL capacity from Plant 6 in Dahej by mid-2026. Investments targeted at technologies to open higher-value portfolio opportunit

Future growth expectations in sales/revenue/volumes?

Glenmark Life Sciences expects high single-digit growth in Glenmark Pharma (GPL) business from FY '24 base. Overall FY '25 top-line growth is projected at low to mid-teens, supported by a robust external business and expected recovery in the Japanese market. Volume growth is anticipated around 10% to 11% with a price erosion of approximately 4% to 4.5%. The CDMO segment is expected to see revenue growth, with plans to increase the portfolio, aiming for about INR 500-600 crores in 4 years and potentially INR 1,000 crores longer term. Capacity expansions at Ankleshwar and Dahej operation

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark Life Sciences expects overall revenue growth in FY '25 to be low to mid-teens percentage, driven by a high single-digit growth in Glenmark business (Generic API) and robust external business including CDMO and Japan market recovery. EBITDA margins are projected in the range of 28% to 30%, considering a 100-150 basis points reduction due to discontinuation of PLI benefits. The company anticipates volume growth of around 10-11%, with a price erosion of 4-4.5%. One-time employee bonus costs, which impacted FY '24 margins, are expected to normalize from Q1 FY '25 onward. Capacity expansio

Current/ Expected Orderbook/ Pending Orders?

Glenmark Life Sciences reports a strong order book for the coming quarters despite recent supply chain disruptions. Demand across most markets remains stable, with the exception of Japan, where inventory destocking is ongoing but expected to recover in H2 FY'25. The company anticipates robust growth in both Generic API and CDMO businesses supported by new capacity additions. There is no explicit quantification of the exact pending order value disclosed in the call. Business visibility typically spans 1 to 2 quarters, allowing capacity to be scaled within approximately 5-6 months when new busin

IN US

Sale is live|00:00:00left today

Alivus Life Sciences LtdQ1 FY24Pharmaceuticals & Biotechnology

Alivus Life Sciences Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,108P/E: 22.7Market Cap: ₹12.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Glenmark Life Sciences expects high single-digit growth in Glenmark Pharma (GPL) business from FY '24 base.
→Overall FY '25 top-line growth is projected at low to mid-teens, supported by a robust external business and expected recovery in the Japanese market.
→Volume growth is anticipated around 10% to 11% with a price erosion of approximately 4% to 4.5%.
→The CDMO segment is expected to see revenue growth, with plans to increase the portfolio, aiming for about INR 500-600 crores in 4 years and potentially INR 1,000 crores longer term.
→Capacity expansions at Ankleshwar and Dahej operational beginning Q1 FY '25 will support growth.
→The high-potency API pipeline (with 17 APIs and a $37 billion addressable market) will contribute significantly starting about 2 years from now.
→Despite some Q4 delays due to geopolitical issues and policy alignment, order books remain strong, supporting growth outlook.

Margin guidance

Category 4

→Glenmark Life Sciences expects overall revenue growth in FY '25 to be low to mid-teens percentage, driven by a high single-digit growth in Glenmark business (Generic API) and robust external business including CDMO and Japan market recovery.
→EBITDA margins are projected in the range of 28% to 30%, considering a 100-150 basis points reduction due to discontinuation of PLI benefits.
→The company anticipates volume growth of around 10-11%, with a price erosion of 4-4.5%.
→One-time employee bonus costs, which impacted FY '24 margins, are expected to normalize from Q1 FY '25 onward.
→Capacity expansions in Ankleshwar and Dahej starting FY '25 Q1 and subsequent phased additions are expected to support future growth.
→The company foresees stable profitability with adjusted EBITDA margins around 31.8% after one-time adjustments in FY '24.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any new fundraising through debt or equity in the transcript.
→The company remains a net debt free company as of March 31, 2024.
→There is mention of increased growth capital available with the new promoter Nirma Limited, but this refers to internal capital allocation rather than external fundraising.
→Capex plans are underway, with INR129 crores spent in FY '24 and new capacities starting operations in FY '25.
→Management focuses on calibrated capacity expansion based on business visibility, using existing resources.
→No indications or plans disclosed for raising funds through debt or equity in the near future.

Order book

Yes

→Glenmark Life Sciences reports a strong order book for the coming quarters despite recent supply chain disruptions.
→Demand across most markets remains stable, with the exception of Japan, where inventory destocking is ongoing but expected to recover in H2 FY'25.
→The company anticipates robust growth in both Generic API and CDMO businesses supported by new capacity additions.
→There is no explicit quantification of the exact pending order value disclosed in the call.
→Business visibility typically spans 1 to 2 quarters, allowing capacity to be scaled within approximately 5-6 months when new business arises.
→The company is actively managing supply chain challenges caused by the Red Sea crisis to fulfill orders timely.
→Overall, the outlook remains positive with strong order inflows and growth capital available for expansion.

Capex plans

Yes

→FY '25 Capex: Around INR340 crores planned.
→Major part (~INR140 crores) allocated for greenfield site development at Sholapur.
→Remaining capex to complete brownfield projects at Ankleshwar and Dahej.
→Regular maintenance, R&D, and quality-related capex also included.
→Capacity additions planned: ~208 KL at Ankleshwar (Plant 18), ~35 KL in pharma area 4 at Dahej.
→Sholapur capacity (approx. 500 KL) expected by late FY '26, with phased commissioning.
→Potential additional 120 KL capacity from Plant 6 in Dahej by mid-2026.
→Investments targeted at technologies to open higher-value portfolio opportunities with commercialization expected in 2-3 years.
→Strategy includes calibrated capacity expansion triggered by business visibility, enabling capacity buildout within 5-6 months if needed.
→Increased growth capital with new promoter Nirma to support expansion and new initiatives.

How does Alivus Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alivus Life Sciences Ltd

Rev 3Mar 4

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Alivus Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio